Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries

Autor: Heintjes EM, Bezemer ID, Prieto-Alhambra D, Smits E, Booth HP, Dedman D, He Y, Hoti F, Vehkala M, de Vogel S, Robinson NJ, Appenteng K, Penning-van Beest FJA

Publikováno v: Clinical Epidemiology, Vol Volume 12, Pp 423-433 (2020)

Edith M Heintjes,1 Irene D Bezemer,1 Daniel Prieto-Alhambra,2,3 Elisabeth Smits,1 Helen P Booth,4 Daniel Dedman,4 Ying He,3 Fabian Hoti,5 Minna Vehkala,5 Stefan de Vogel,6 Noah Jamie Robinson,6 Kwame Appenteng,7 Fernie JA Penning-van Beest1 1PHARMO I

Externí odkaz: https://doaj.org/article/030b47749daa44f5977e5b93d1bb3fd7

Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands.

Autor: Swart KMA; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands. pharmo@pharmo.nl., Baak BN; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands., Lemmens L; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands., Penning-van Beest FJA; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands., Bengtsson C; IQVIA, Real World Solutions, Solna, Sweden., Lobier M; IQVIA, Real World Solutions, Espoo, Finland., Hoti F; IQVIA, Real World Solutions, Espoo, Finland., Vojinovic D; IQVIA, Real World Solutions, Amsterdam, The Netherlands., van Burk L; AstraZeneca, The Hague, The Netherlands., Rhodes K; AstraZeneca, Cambridge, UK., Garbe E; Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany., Herings RMC; PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands.; Amsterdam Public Health Research Institute, Amsterdam UMC Location Vrije University Amsterdam, Amsterdam, The Netherlands., Nordon C; AstraZeneca, Cambridge, UK., Simons SO; Department of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.

Publikováno v: Respiratory research [Respir Res] 2023 Nov 21; Vol. 24 (1), pp. 293. Date of Electronic Publication: 2023 Nov 21.

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.

Autor: Vistisen D; Steno Diabetes Center Copenhagen, Copenhagen, Denmark.; Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Carstensen B; Steno Diabetes Center Copenhagen, Copenhagen, Denmark., Elisabetta P; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Lanzinger S; Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany.; German Centre for Diabetes Research (DZD), Munich-Neuherberg, Germany., Tan EC; Department of Health Service Administration, China Medical University, Taichung, Taiwan., Yabe D; Yutaka Seino Distinguished Centre for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan.; Department of Diabetes, Metabolism and Endocrinology/Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.; Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan.; Preemptive Food Research Centre, Gifu University Institute for Advanced Study, Gifu, Japan., Kim DJ; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea., Sheu WH; Insititute of Molecular and Genomic Medicine, National Health Research Institutes, Taipei City, Taiwan., Melzer-Cohen C; Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel-Aviv, Israel., Holl RW; Institute for Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany., Núñez J; Department of Cardiology, Hospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, CIBER Cardiovascular, Valencia, Spain., Ha KH; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea., Halvorsen S; Department of Cardiology, Oslo University Hospital Ullevål, University of Oslo, Oslo, Norway., Langslet G; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Lipid Clinic, Oslo University Hospital, Oslo, Norway., Karasik A; Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel-Aviv, Israel., Nyström T; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden., Niskanen L; Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital, Lahti, Finland.; University of Eastern Finland, Kuopio, Finland., Guleria S; IQVIA, Goteborg, Sweden., Klement R; IQVIA, Tartu, Estonia., Carrasco M; Boehringer Ingelheim Pharmaceuticals, Inc., Barcelona, Spain., Foersch J; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Shay C; Boehringer Ingelheim Pharmaceuticals USA, 00 Ridgebury Road, Ridgefield, CT, 06877, USA. christina.shay@boehringer-ingelheim.com., Koeneman L; Lilly Deutschland GmbH, Bad Homburg, Germany., Hoti F; IQVIA, Espoo, Finland., Farsani SF; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Khunti K; Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK., Zaccardi F; Leicester Real World Evidence Unit, Leicester Diabetes Centre, University of Leicester, Leicester, UK., Subramanian A; Institute of Applied Health Research, University of Birmingham, Birmingham, UK., Nirantharakumar K; Institute of Applied Health Research, University of Birmingham, Birmingham, UK.; Midlands Health Data Research UK, Birmingham, UK.; DEMAND Hub, University of Birmingham, Birmingham, UK.

Publikováno v: Cardiovascular diabetology [Cardiovasc Diabetol] 2023 Aug 31; Vol. 22 (1), pp. 233. Date of Electronic Publication: 2023 Aug 31.

Validation of safety outcomes in routinely collected data: Lessons learned from a multinational postapproval safety study.

Autor: Arena PJ; Global Medical Epidemiology, Pfizer Inc., New York, New York, USA.; Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, California, USA., Huang K; Global Medical Epidemiology, Pfizer Inc., New York, New York, USA., Löfling L; Centre for Pharmacoepidemiology, Karolinska Institutet, Karolinska University Hospital SE, Stockholm, Sweden.; Department of Research, Cancer Registry of Norway, Oslo, Norway., Bahmanyar S; Centre for Pharmacoepidemiology, Karolinska Institutet, Karolinska University Hospital SE, Stockholm, Sweden., Mo J; Safety Surveillance Research, Pfizer Inc., New York, New York, USA., Schachterle SE; Global Medical Epidemiology, Pfizer Inc., New York, New York, USA., Nunes AP; Optum Inc., Boston, Massachusetts, USA.; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, USA., Smits E; PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands., Juuti R; EPID Research, Espoo, Finland., Hoti F; EPID Research, Espoo, Finland., Korhonen P; EPID Research, Espoo, Finland., Adelborg K; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark., Sundbøll J; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark., Rasmussen TR; Department of Respiratory Diseases and Allergology, Aarhus University Hospital, Aarhus N, Denmark., Løkke A; Department of Medicine, Little Belt Hospital, Vejle, Denmark.; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Ehrenstein V; EPID Research, Espoo, Finland.

Publikováno v: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2023 May; Vol. 32 (5), pp. 592-596. Date of Electronic Publication: 2022 Dec 29.